Anavex Life Sciences Corp (AVXL)

[falconer66a]

But What Could This Guy Know?

We therefore confirmed the role of endogenous neuroprotection system in neurodegenerative processes and identified S1R agonists as potent neuroprotective and putatively disease-modifying agents.

http://alzheimers-dementia.conferenceseries.com/abstract/2015/development-of-sigma-1-receptor-agonists-as-neuroprotectants-in-alzheimers-disease-and-related-dementia

After graduating chemical engineer from ENSCM (Montpellier, France) in 1987, Tangui Maurice got his PhD in neuropharmacology in 1990. He made 2 post-doctoral fellowships at the Jouveinal research institute (Paris) and Nagoya University Hospital and Meijo University (Nagoya, Japan). He joined CNRS in 1992 starting to work on sigma-1 receptors . He is now team leader at INSERM U. 710 (U. 1198 since 01/01, 2015). He gots [SIC] 120+ publications and 4 patents. Tangui Maurice also created a CRO company, Amylgen, co-founded with 3 scientists from university and industry, where he is currently acting as CSO.